Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

NCT04965831 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Lung Adenocarcinoma

Interventions

DRUG: Furmonertinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Collaborators

[object Object]